首页> 外文期刊>Acta bio-medica: Atenei Parmensis >Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, and Lactobacillus delbrueckii LDD01) in patients undergoing bowel preparation
【24h】

Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, and Lactobacillus delbrueckii LDD01) in patients undergoing bowel preparation

机译:接受肠准备的患者中的植物乳杆菌LP01,乳酸乳杆菌亚种cremoris LLC02和德氏乳杆菌LDD01)

获取原文
获取外文期刊封面目录资料

摘要

Bowel preparation (BP) for colonoscopy induces significantly changes in gut microbiota and elicit intestinal symptoms. Impaired microbiota causes an intestinal dysbiosis. Consequently, probiotics may counterbalance the disturbed microbiota after BP. The current survey evaluated the efficacy and safety of Abincol ? , an oral nutraceutical containing a probiotic mixture with Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 millions of living cells), and Lactobacillus delbrueckii LDD01 (200 millions of living cells), in 2,979 outpatients (1,579 males and 1,400 females, mean age 56 years) undergoing BP. Patients took 1 stick/daily for 4 weeks after colonoscopy. Abincol ? significantly diminished the presence and the severity of intestinal symptoms and improved stool form. In conclusion, the current survey suggests that Abincol ? may be considered an effective and safe therapeutic option in the management of patients undergoing BP.
机译:用于结肠镜检查的肠道制剂(BP)会引起肠道菌群的显着变化,并引起肠道症状。微生物群受损会引起肠道营养不良。因此,益生菌可以抵消BP后受干扰的微生物群。当前的调查评估了Abincol®的疗效和安全性。 ,这是一种口服营养保健品,在2,979名门诊患者中含有益生菌混合物,其中包括益生菌混合物与植物乳杆菌LP01(10亿个活细胞),乳酸乳杆菌cremoris LLC02亚种(8亿个活细胞)和德氏乳杆菌LDD01(2亿个活细胞)。男性和1400名女性,平均年龄为56岁)接受BP治疗。结肠镜检查后患者每天服用1支/棒,持续4周。阿宾科尔?大大减少了肠道症状的存在和严重程度,并改善了粪便形式。总之,当前的调查表明Abincol?在接受BP治疗的患者中,可被视为一种有效且安全的治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号